The global checkpoint inhibitors market should reach $29.3 billion by 2023 from $14.9 billion in 2018 at a compound annual growth rate (CAGR) of 14.4% for the period of 2018-2023.
- 21 data tables and 43 additional tables
- An overview of the global market for checkpoint inhibitors
- Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Discussion of the market landscape and innovative strategies, and the areas of unmet medical needs
- Information on the biomarker development, immune modulation, innovative delivery technologies, and the future landscape
- Market analysis for CP inhibitors, including PD-1/PD-L1 agents, CTLA-4 agents, TIM-3 agents, LAG-3 agents, IDO-1 agents, and SIRPα agents
- Comprehensive company profiles of major players in the industry, including Agenus, Inc., BeiGene, BIOCAD, Forty Seven, Inc., Seattle Genetics, Inc., Shanghai Cell Therapy, Tesaro, Inc. and Xencor
This report on checkpoint inhibitors provides a detailed analysis of the market based on approved clinical and preclinical developmental candidates that target PD-1/PD-L1, CTLA-4, IDO-1, LAG-3, TIM-3, and CD47/SIRPα. The report analyzes the market trends, key medical needs and provides insights into recent advances in the modulation of checkpoint inhibition in the treatment of cancer through the development of fully human monoclonal antibodies, bispecific antibodies, fusion proteins, and chimeric antigen receptor (CAR) T cells.
Dr. Cheryl L. Barton has more than 10 years of practical pharmaceutical research experience with a leading pharmaceutical company and has served as a Pan-European Pharmaceutical analyst with a European bank. Dr. C. L. Barton Ltd. aims to provide independent, tailor-made, pharmaceutical thematic research to investment houses. Research reports combine independent scientific analysis with patient- and prescription-based models to forecast the potential sales growth of key developmental drugs and to isolate the key drivers within the pharmaceutical sector. For further information, visit www.pharmavision.co.uk.
When do I get the report?
Most reports are fulfilled immediately. In some cases, it could take up to 24 hours.
In what format does this report get delivered to me?
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
What are the free reports included in my purchase?
They consist of a collection of current reports from various partner publishers scanning multiple industries.
What is the difference between BCC Research and BCC Publishing?
BCC Research curates thousands of reports from different sources and provides access to this content to our clients. BCC Publishing is the publication arm of BCC Research (one of several publishers in our portal).
What reports do I get 'discounts' on with my purchase?
All reports. BCC Publishing reports will be available for a 50% discount. All other partner publishers are also available at deeply discounted rates.
Where are you located?
Wellesley Massachusetts, just outside of Boston, Massachusetts, USA.
How long has BCC Research been around?
We are approaching our 50 year anniversary in 2021!
What if I want you to invoice me for payment via Purchase Order?
Simply choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.
What if I have a question about your reports?
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times, and included in every purchase, to help our customers find the research they need-when they need it.
Can I share this report with my team?
Absolutely yes, with the purchase of additional user licenses.
Can I use your research in my presentation?
Absolutely yes, so long as the publisher is properly cited.